Scancell and ImmuneRegen look at combining vaccine technologies
This article was originally published in Scrip
Executive Summary
UK therapeutic cancer vaccine developer Scancell Holdings and ImmuneRegen BioSciences are to investigate whether their technologies could be combined to develop improved product efficacy.